Development of a new antibody drug to treat congenital tooth agenesis

Abstract:

Congenital tooth agenesis is one of the most common developmental anomalies of the dentition and includes hypodontia and oligodontia. Current treatment modalities, such as removable prostheses, fixed prostheses, and dental implants, are effective in restoring function and aesthetics but are unable to regenerate natural teeth. Therefore, regenerative approaches have emerged as promising alternatives for biological tooth replacement.

Recent studies have identified uterine sensitization-associated gene-1 (USAG-1), also known as SOSTDC1, as a key negative regulator of bone morphogenetic protein (BMP) and Wnt signaling pathways, both of which play essential roles in tooth development. Experimental investigations using genetically modified mouse models demonstrated that suppression of USAG-1 activity enhances odontogenesis and promotes the formation of supernumerary teeth. Moreover, crossing USAG-1-deficient mice with models of congenital tooth agenesis successfully restored arrested tooth development.

Based on these findings, anti-USAG-1 neutralizing antibodies were developed as potential therapeutic agents. Administration of these antibodies was shown to rescue tooth germs that had failed to develop and to stimulate the formation of complete teeth from endogenous tissues. Furthermore, a humanized anti-USAG-1 antibody has been established as a candidate for future clinical application.

These findings represent a significant breakthrough in regenerative dentistry and suggest that molecular-targeted antibody therapy may provide a novel biological treatment for patients with congenital tooth agenesis. Nevertheless, further preclinical studies and clinical trials are required to evaluate its long-term safety, efficacy, and therapeutic outcomes before routine use in humans